WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Firm News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Emergent BioSolutions, which offers specialized products to healthcare providers and governments to address medical needs and emerging health threats, announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal is expected to close by the end of the year.

The WilmerHale team representing Emergent BioSolutions was led by Jeffrey Hermanson and includes Belinda Juran, Sam Rothberg, Alex Civetta, Jasmine Haddad, Hartmut Schneider, Julie Hogan Rodgers and Bruce Manheim.

To learn more about the acquisition, read Emergent BioSolutions' press release.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel